On June 3, 2024, the board of directors of Fate Therapeutics, Inc. appointed J. Scott Wolchko, the Company?s President and Chief Executive Officer as the Company?s principal financial and accounting officer, effective immediately. Mr. Wolchko previously served as the Chief Financial Officer of the Company from the commencement of its operations until August 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.41 USD | -4.48% | -9.55% | -8.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.82% | 388M | |
+14.84% | 121B | |
+18.31% | 112B | |
+4.45% | 22.57B | |
-18.26% | 20.82B | |
-16.75% | 16.19B | |
-42.36% | 16.17B | |
-14.23% | 16.3B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Appoints J. Scott Wolchko as Principal Financial and Accounting Officer